Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations for Fosamax in Pennsylvania

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Occupational Exposure Concerns

For decades, general health and science communication has served as the foundation for public understanding of medical risks and treatment options. This legacy context emphasized broad awareness of pharmaceutical benefits and side effects, often framed within population-level guidelines. As the domain of mass production evolved, however, the focus shifted from generalized health messaging to more targeted concerns about specific exposures in manufacturing and distribution environments. The transition from a general health framework to an occupational exposure perspective requires careful attention to how large-scale production processes can introduce unique risk profiles for workers and end-users alike. In particular, the widespread manufacture and handling of bisphosphonate medications, such as Fosamax, created new pathways for exposure that were not fully anticipated in earlier health education models. The concern now centers on how prolonged or repeated contact with these compounds—whether through direct handling in production lines or through patient consumption—may correlate with adverse outcomes like osteonecrosis of the jaw. This pivot from general health information to occupational exposure awareness underscores the need for precise legal and regulatory timelines, such as the statute of limitations in Pennsylvania, to address claims arising from such exposures.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the legacy of general health communication, the specific risks associated with Fosamax (alendronate) require focused examination. Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction, local infection, or delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Clinical Presentation and Risk Factors for ONJ

The clinical presentation of ONJ often involves pain, swelling, infection, and exposed bone in the mandible or maxilla, and diagnosis is typically based on clinical examination and imaging. The mechanistic pathways linking Fosamax to ONJ are not fully detailed in the provided evidence, but bisphosphonates like alendronate inhibit osteoclast activity, which can suppress bone remodeling. This suppression may impair the jaw's ability to heal after minor trauma, such as tooth extraction, leading to avascular necrosis. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk of ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Timeline of Exposure and Symptom Onset

The timeline between exposure to Fosamax and documented harm from ONJ can vary. The time to onset of symptoms after starting the drug can range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In clinical studies, most patients had relief of symptoms after discontinuing the drug, but a subset experienced recurrence when rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is considered rare; one study noted that the incidence of atypical femoral fracture or ONJ was uncommon and rare, respectively (https://pubmed.ncbi.nlm.nih.gov/42046648/). Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/).

Adequacy of Warnings and Legal Implications

Regarding the adequacy of warnings, the Fosamax label includes a specific section on osteonecrosis of the jaw under "Warnings and Precautions" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also notes that in placebo-controlled clinical studies, the percentages of patients with symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This may raise questions about whether the warnings adequately convey the risk, particularly for patients who develop ONJ after prolonged use or after dental procedures. For affected patients in Pennsylvania, attorney-related considerations involve the statute of limitations for filing a claim related to Fosamax and ONJ. The statute of limitations for personal injury claims in Pennsylvania is generally two years from the date the injury was discovered or should have been discovered. Given the variable timeline between exposure and symptom onset—ranging from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)—patients must be aware of when their injury became apparent. The risk of ONJ may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1), meaning that patients who have taken Fosamax for several years may be at higher risk, and the discovery of ONJ could occur long after initial exposure. Patients should consult with an attorney to determine the applicable statute of limitations in their specific case, as delays in diagnosis or symptom recognition could affect the filing deadline.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Pennsylvania?

In Pennsylvania, the statute of limitations for personal injury claims, including those related to Fosamax and osteonecrosis of the jaw, is generally two years from the date the injury was discovered or should have been discovered. Given the variable onset of ONJ symptoms, which can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), it is crucial to consult an attorney promptly to ensure the filing deadline is met.

What are the known risk factors for developing ONJ from Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate exposure.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.